Description: Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of oncology biologics. Its product pipeline includes KN046, a bispecific monoclonal antibody (BsAb) immune checkpoint inhibitor, that targets clinically-validated immune checkpoints, including programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); and KN026, a next generation anti-human epidermal growth factor receptor 2 (HER2) BsAb that is in Phase III clinical trials for treatment of HER2-positive breast cancer; and phase I and II clinical trial treatment of heavily pre-treated HER2 cancers, as well as Phase II clinical trial to treat unreselectable or metastatic HER2-positive solid tumors. The company's product pipeline also comprises KN035, an injectable PD-L1 inhibitor that is in phase III clinical trials for neoadjuvant/adjuvant treatment of non-small cell lung cancer and endometrial cancer; and KN019, a CTLA-4-based immunosuppressant fusion protein, for auto-immune diseases and oncology treatment-induced immune disorders. In addition, its product pipeline also includes KN052, a PD-L1/OX40 bispecific antibody that prevents the immune escape of tumor cells; JSKN003, a biparatopic HER2-targeting antibody-drug conjugate that is in phase I/II clinical trial for the treatment of HER2-expressing advanced or metastatic solid tumors; and JSKN033, a subcutaneous antibody-drug conjugate to treat HER2-expressing advanced or metastatic solid tumors. The company was founded in 2008 and is headquartered in Suzhou, the People's Republic of China.
Home Page: www.alphamabonc.com
No. 175 Fangzhou Road
Suzhou,
China
Phone:
86 512 6285 0800
Officers
| Name | Title |
|---|---|
| Dr. Ting Xu Ph.D. | Founder, Executive Chairman & CEO |
| Ms. Yang Liu | VP of Corporate Operations & Executive Director |
| Mr. Yumin Wan | Vice President of Government Affairs & Public Relations |
| Dr. Mike Liu M.B.A., Ph.D. | Senior Vice President of Business Development |
| Mr. Jing Han | Chief Commercial Officer |
| Ms. Lok Yee Chan A.C.I.S., A.C.S. | Joint Company Secretary |
| Ms. Qiulan Cheng | Joint Company Secretary |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.0408 |
| Price-to-Sales TTM: | 1.7028 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 429 |